October 01, 2014 2:27 PM ET

Pharmaceuticals

Company Overview of OctoPlus N.V.

Executive Profile

Dharminder S. Chahal

Observer to Supervisory Board, Innate Pharma S.A.
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 4 different industries.

See Board Relationships
38--

Background

Mr. Dharminder S. Chahal is the Owner and Managing Director of Exponential BV in which capacity Mr. Chahal acts as consultant to Van Herk Investments. Mr. Chahal serves as an Observer To Supervisory Board of Innate Pharma S.A. Mr. Chahal has built an extensive network in the life science industry and a strong track record in direct involvement of complex corporate transactions including the sale of the stake of Van Herk Investments in Crucell to Johnson and Johnson, ...

Corporate Headquarters

Zernikedreef 12
Leiden, Zuid-Holland 2333 CL

Netherlands

Phone: 31 71 524 4044
Fax: 31 71 524 4043

Board Members Memberships

2013-Present
Director and Member of Audit Committee

Education

Master's Degree
Erasmus University
Master's Degree
Delft University of Technology

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OctoPlus N.V., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.